ISRCTN40367841已完成未知
A pilot study and randomised trial of a multicomponent mobile-health based intervention compared with usual care to improve outcomes in chronic obstructive pulmonary disease
Oxford University (UK)0 个研究点目标入组 295 人开始时间: 2012年10月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 295
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 21/11/2013:
- •1. Aged > 40 years
- •2. A forced expiratory volume in 1 second (FEV1) post-bronchodilatory <80% AND predicted ratio of FEV1 to forced vital capacity (FVC) <0.70 OR clinical decision of suitability for patients who are unable to provide a spirometry reading (on clinical grounds) at full assessment. The patient must have prior clinical evidence of COPD, i.e. obstructive spirometry within the last ten years; radiological evidence of emphysema.
- •3. Smoking history > 10 pack years
- •4. MRC Dyspnoea scale >or = to 2
- •5. Registered with a general practice and with an exacerbation of COPD requiring hospital admission or home treatment in the previous year, or referred for pulmonary rehabilitation
- •6. Absence of other significant lung disease
- •7. Absence of chronic heart failure defined by the New York Heart Association classification system as severe (Grade IV)
- •8. Able to give informed consent
- •9. Able to complete questionnaires and use the mHealth system
- •10. Life expectancy of >3 months
- •11. No recent participation in a COPD self-management clinical trial programme
- •12. Patients unable to transmit data from the tablet due to insufficient internet access will not be eligible to enter the study
- •Previous inclusion criteria:
- •1. Aged > 40 years
- •2. Forced expiratory volume in 1s (FEV1) post-bronchodilatory <70%
- •3. Predicted ratio of FEV1 to forced vital capacity (FVC) <0.70
- •4. Smoking history > 10 pack years
- •5. MRC Dyspnoea scale >or = to 2
- •6. Registered with a general practice and with an exacerbation of COPD requiring hospital admission or home treatment in the previous year, or referred for pulmonary rehabilitation
- •7. Absence of other significant lung disease
- •8. Absence of chronic heart failure
- •9. Able to give informed consent
- •10. Able to complete questionnaires and use the mHealth system
- •11. Life expectancy of >3 months
- •12. No recent participation in a COPD self-management clinical trial programme
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
已完成
不适用
Testing strategies to improve breathlessness and related symptoms in people with lung cancerLung cancerACTRN12612000925842Queensland University of Technology18
进行中（未招募）
1 期
A study to test the effectiveness and safety of bacteria called Bifidobacterium breve in patients with COVID-19 infectionsSymptoms of Covid-19 infectionMedDRA version: 20.0Level: LLTClassification code 10061986Term: SARSSystem Organ Class: 100000004862EUCTR2020-001597-30-GB4D pharma plc90
已完成
4 期
Pilot trial evaluating the efficacy of different antibiotic treatments for the treatment of prosthetic joint infection in adults who have undergone joint replacement surgery.Prosthetic joint infectionInfection - Studies of infection and infectious agentsACTRN12617000127303John Hunter Hospital60
招募中
4 期
Effect of combination of clomiphene citrate and Letrozole in infertile patients with PCOSCTRI/2024/03/064893Post graduate institute of medical sciences and research
终止
不适用
The MultICath StudyTopic: Primary Care, RenalSubtopic: Primary Care (Renal Disorders), Renal (Renal Disorders)Disease: All Diseases, All Renal DisordersUrological and Genital DiseasesCatheterisationISRCTN68472863niversity of Southampton500